Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by angelbanua1on Dec 01, 2020 9:52am

481 Views

Post# 32008557

Blood Stream

[url=https://https://b.link/MedicalMarketsMightSurgeDespite]This might keep you updated. Try it out now! [/url]

It is said that this revolutionary inhaler device delivers measured amounts of green leaf directly into the systemic blood stream through the lungs, and with a short burst of aerosolized medicine. It is also approx 98% bioavailable, with only around 2% lost during exhalation.

Felt great that I found this! Check Disclaimer on my Profile

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"